The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Changing Patterns Of Immunity Following Large Scale Malaria Control Programs In The South West Pacific
Funder
National Health and Medical Research Council
Funding Amount
$299,564.00
Summary
People can develop partial immunity to malaria, which requires ongoing exposure to infection to be maintained. If exposure to infections is completely prevented, people can lose the immunity it has taken them years to develop. In the context of significant ongoing malaria bednet control efforts in the South West Pacific, we will investigate loss or maintenance of the malaria-immune state. This is important for vaccine development and to help us define risk of rebound disease.
This research will advance the development of a novel vaccine strategy based on duck hepatitis B virus-like particles (VLPs). These VLPs can be engineered to contain parts of other viruses such as Hepatitis C, HIV or Measles, and have been shown to produce strong antibody responses in mice. Detailed information on the cellular and antibody responses to these VLP vaccines will be aligned with GLP processes to support future clinical trials in man, providing support for the development of urgently ....This research will advance the development of a novel vaccine strategy based on duck hepatitis B virus-like particles (VLPs). These VLPs can be engineered to contain parts of other viruses such as Hepatitis C, HIV or Measles, and have been shown to produce strong antibody responses in mice. Detailed information on the cellular and antibody responses to these VLP vaccines will be aligned with GLP processes to support future clinical trials in man, providing support for the development of urgently needed vaccines against a range of infectious diseases.Read moreRead less